IS IT HIT OR HAT? M&M Conference 3/28/02. HAT Mild thrombocythopenia 100K- 130K Incidence: 25% 1-4 days after starting heparin Non immune-mediated (direct.

Slides:



Advertisements
Similar presentations
Farmaci usati prima dellintervento Basi farmacologiche del loro uso La prevenzione del tromboembolismo.
Advertisements

HEPARIN INDUCED THROMBOCYTOPENIA: HIT HAPPENS
Chapter 31 Antithrombotic therapy August 8, 2005.
Controversies in the management of Pulmonary Embolism
Heparin-Induced Thrombocytopenia DR VINOD G V. HIT An immunoglobulin-mediated adverse drug reaction characterized by: –platelet activation –thrombocytopenia.
Treatment of Acute Pulmonary Embolism
Chapter Six Venous Disease Coalition Acute Management of VTE VTE Toolkit.
VTE in abdominal-pelvic surgery patients
Prophylaxis of Venous Thromboembolism
Risk of VTE – when is anticoagulation required treatment of VTE – what is optimum anticoagulant survival advantage with heparins new anticoagulants – how.
 Incidence rate (symptomatic): 1%  ½ occur after discharge  We don’t understand which patients are at highest risk.
Heparin-Induced Thrombocytopenia Lawrence Rice, MD Chief, Division of Hematology Clinical Chief, Hem/Onc Service The Methodist Hospital Weill Cornell Medical.
Potential of the Factor Xa Inhibitor Rivaroxaban for the Anticoagulation Management of Patients with Heparin-Induced Thrombocytopenia Jeanine M. Walenga,
The HITS Keep Coming Marc J. Kahn, MD, MBA, FACP Peterman-Prosser Professor Tulane University School of Medicine New Orleans, LA.
Preventing Anticoagulation Errors with Clinical Dashboards Dan Johnson, Pharm.D., BCPS August 3, 2011.
HEPARIN INDUCED THROMBOCYTOPENIA GALILA ZAHER MBB ch, dip C Path, MRC Path.
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.
Done by : Ali Al-Thubyani, Pharm D Candidate Supervised by : Hend Metwali, Associate Clinical Pharmacist.
Pulmonary Embolism. Definition: Sudden lodgment of a blood clot in a pulmonary artery with subsequent obstruction of blood supply to the lung parenchyma.
Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.
Total Joint Replacement
Heparin-Induced Thrombocytopenia (HIT)
Venous Thromboembolism
Cancer-Associated Thrombosis
To Clot Or Not To Clot… Emergency Care for Coagulation Disorders/Conditions Rebecca Goldsmith Pediatric Thrombosis/Hemophilia Nurse McMaster Children’s.
Case Report Pneumology Dr. David Tran A&E, FVHospital Medical meeting September 28 th, 2011.
The Role of Thromboprophylaxis in Elective Spinal Surgery The Role of Thromboprophylaxis in Elective Spinal Surgery VA Elwell, N Koo Ng, D Horner & D Peterson.
Pulmonary Embolism Treatment in Cancer - Is It Different 34th Brazilian Thoracic Conference 6th ALAT Congress 5th Brazil-Portugal Congress Brazilia/DF.
 Background  Cost  Benefit  Complication.
Thrombophilia (Hypercoagulable States) Abdulkareem Almomen, MD Professor of Medicine & Hematology, King Saud University MED 341, Feb.2014.
VTE Prevention In Action Interactive Case Scenarios.
Applications of bivalirudin in interventional cardiology
Approach To Pneumonia. Pneumonia Importance Mechanism Classification & its benefit Diagnosis Treatment.
HEPARIN INDUCED THROMBOCYTOPENIA (HIT)
Heparin induce thrombocytopenia. Presented by the American Society of Hematology, adapted in part from the: American College of Chest Physicians Evidence-Based.
Deep vein thrombosis Pulmonary embolism Deep vein thrombosis Pulmonary embolism Venous Thromboembolism TreatmentTreatment …All the same?
Venous Thromboembolism Prophylaxis for Medical Inpatients Heather Hofmann, rev. 4/18/14 DSR2 Mini Lecture.
Chapter Seven Venous Disease Coalition Long-Term Management of VTE VTE Toolkit.
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Shujuan Cheng,MD; Hongbing Yan,MD Beijing Anzhen Hospital Capital Medical University, Beijing China Argatroban for Severe Thrombocytopnia after Primary.
Prophylaxis Diagnosis Treatment Venous Thromboembolism Management.
Peri-Operative anticoagulation /antiplatelet therapy A Shift in Paradigm BMHGT04/29/09.
1 Clinical Pharmacy Venous thromboembolism Rowa’ Al-Ramahi.
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer Agnes Y. Y. Lee, MD, MSc; Pieter W. Kamphuisen, MD,
Treatment and Prevention of Heparin- Induced Thrombocytopenia Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism ‘ The PADIS-PE Trial’ Nate Peyton.
Heparin – Lovenox - Coumadin Charnelle Lee, RN, MSN.
Heparin-Induced Thrombocytopenia Farzaneh Dastan Assistant Professor of Pharmacotherapy, Pharm D, BCPS SBMU.
Venous Thromboembolism Prophylaxis for Medical Inpatients
Elvira Maličev Blood Transfusion Centre of Slovenia
Treatment and Prevention of Heparin-Induced Thrombocytopenia
Anticoagulants in the Treatment of Venous Thromboembolism
HIT: The Consequences of Heparin’s Nonspecific Binding to Platelet Factor 4 Heparin is neutralized by platelet factor 4, (PF4), which is present in high.
Contemporary Diagnosis and Management of Unstable Angina
by Nadine Martel, James Lee, and Philip S. Wells
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
Heparin induced thrombocytopenia
A Case Challenge: Anticoagulant Choices for Acute PE
Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with.
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
Succinct Review of the New VTE Prevention and Management Guidelines
Early Management of NSTE-ACS: From the ED to the Cath Lab
Extraordinary Cases in VTE
How I treat cancer-associated venous thromboembolism
Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.
Disease Burden of VTE Phases of VTE Treatment.
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
Heparin-induced thrombocytopenia
Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.
Presentation transcript:

IS IT HIT OR HAT? M&M Conference 3/28/02

HAT Mild thrombocythopenia 100K- 130K Incidence: 25% 1-4 days after starting heparin Non immune-mediated (direct interaction between Heparin and platelet) Non thrombogenic Thrombocythopenia resolves after heparin discontinuation

HIT Un expected drop in platelet count Less than 100,000 And about 50% of base line Incidence: 1% to 3% on UFH On Heparin for at least 5 days OR Was on Heparin the last 3 months More with UFH than with LMWH Patient are at high risk of clothing NOT bleeding!

Pathophysiology Heparin has an affinity to PF4 which is found in platelet  granules Heparin-PF4 compleax induce IgG reaction IgG-heparin-PF4 complex attaches to platelet leading to aggregation (cloth)  more PF4 production and so on 80% cross reactivity with LMWH

Clinical manifestation HITTS in 25% VTE > ATE (4X) ATE Stroke. & Limb, bowel, splenic infarction VTE DVT & PE Acute HIT fever, N/V, chest pain Sub acute asymptomatic Delayed: accumulative risk of developing a cloth is 50% in one month

Diagnosis Clinical! Lab tests

Treatment All sources of heparin should be discontinued D/C H2 blockers, quinines and reassess the need for Abx HIT: Danaparoid Lepirudin or Bivalirudin DON’T use warfarin Or LMWH